Current Report Filing (8-k)
March 11 2021 - 8:33AM
Edgar (US Regulatory)
0001083446
false
0001083446
2021-03-11
2021-03-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 11, 2021
APOLLO MEDICAL HOLDINGS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-37392
|
|
95-4472349
|
(State or Other
Jurisdiction
|
|
(Commission File
|
|
(I.R.S. Employer
|
of Incorporation)
|
|
Number)
|
|
Identification
Number)
|
1668 S. Garfield Avenue, 2nd Floor, Alhambra,
CA 91801
(Address of Principal Executive Offices,
and Zip Code)
(626) 282-0288
Registrant’s Telephone Number,
Including Area Code
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Precommencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Precommencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
AMEH
|
Nasdaq Capital Market
|
Item 7.01 Regulation
FD Disclosure.
Apollo Medical
Holdings, Inc. (the “Company”) is scheduled to present at the Barclays Global Healthcare Conference on March 11, 2021.
A copy of certain information to be presented by the Company’s officers at the conference is attached hereto as Exhibit 99.1
and incorporated herein by reference.
The information
contained in this Current Report on Form 8-K, including the exhibit referenced herein, is being furnished and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of
any general incorporation language in such filing. The furnishing of this information will not be deemed an admission as to the
materiality of any information contained herein.
Item 9.01 Financial
Statements and Exhibits
(d) Exhibits.
Forward-Looking Statements
This current report on Form 8-K contains
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements include words such as “forecast,” “guidance,”
“projects,” “estimates,” “anticipates,” “believes,” “expects,” “intends,”
“may,” “plans,” “seeks,” “should,” or “will,” or the negative of these
words or similar words. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially
from those discussed in each such statement. A number of important factors could cause actual results to differ materially from
those included within or contemplated by the forward-looking statements, including, but not limited to, the factors described in
our filings with the Securities and Exchange Commission, including the Company’s most recent annual report on Form 10-K and
any subsequent quarterly reports on Form 10-Q. The Company does not undertake any responsibility to update any of these factors
or to announce publicly any revisions to any of the forward-looking statements contained in this or any other document, whether
as a result of new information, future events, or otherwise.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
APOLLO MEDICAL HOLDINGS, INC.
|
|
|
Dated: March 11, 2021
|
By:
|
/s/
Thomas S. Lam
|
|
Name:
|
Thomas S. Lam,
M.D., M.P.H.
|
|
Title:
|
Co-Chief Executive Officer and President
|
Apollo Medical (NASDAQ:AMEH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apollo Medical (NASDAQ:AMEH)
Historical Stock Chart
From Apr 2023 to Apr 2024